We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis (MUCO TRANSPLAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03357913
Recruitment Status : Completed
First Posted : November 30, 2017
Last Update Posted : November 30, 2017
Sponsor:
Information provided by (Responsible Party):

November 20, 2017
November 30, 2017
November 30, 2017
June 1, 2017
June 1, 2017   (Final data collection date for primary outcome measure)
  • Incidence of co-morbidities after lung transplantation [ Time Frame: 1 year ]

    The incidence rate will be calculated at 1 year follow-up after lung transplantation.

    The comorbidities studied will be:

    • diabetes
    • kidney failure
    • high blood pressure
    • hepatopathies
    • undernutrition
    • osteoporosis
    • neoplasms, and in particular colon cancer
    • gynecological complications (viral and neoplastic)
  • Incidence of co-morbidities after lung transplantation [ Time Frame: 2 years ]

    The incidence rate will be calculated at 2 years follow-up after lung transplantation.

    The comorbidities studied will be:

    • diabetes
    • kidney failure
    • high blood pressure
    • hepatopathies
    • undernutrition
    • osteoporosis
    • neoplasms, and in particular colon cancer
    • gynecological complications (viral and neoplastic)
  • Incidence of co-morbidities after lung transplantation [ Time Frame: 5 years ]

    The incidence rate will be calculated at 5 years follow-up after lung transplantation.

    The comorbidities studied will be:

    • diabetes
    • kidney failure
    • high blood pressure
    • hepatopathies
    • undernutrition
    • osteoporosis
    • neoplasms, and in particular colon cancer
    • gynecological complications (viral and neoplastic)
  • Incidence of co-morbidities after lung transplantation [ Time Frame: 10 years ]

    The incidence rate will be calculated at 10 years follow-up after lung transplantation.

    The comorbidities studied will be:

    • diabetes
    • kidney failure
    • high blood pressure
    • hepatopathies
    • undernutrition
    • osteoporosis
    • neoplasms, and in particular colon cancer
    • gynecological complications (viral and neoplastic)
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis
Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis - Exploratory Study From the French Cohort on 2004-2014.

Pulmonary transplantation is the reference treatment for chronic terminal respiratory failure in patients with cystic fibrosis. These are mainly bi-pulmonary transplants (cardiopulmonary transplants are exceptional). The annual number of pulmonary transplants in France for cystic fibrosis is about 90. In 2013, the transplant involves a total of more than 600 patients with cystic fibrosis. The average age at the time of the transplant is 28.5 years (2013 data, French cystic fibrosis register), compared to 58 years for patients transplanted to all pathologies. Cystic fibrosis accounts for 25% of adult bi-pulmonary grafts. Pediatric transplants are currently very rare.

The median survival after pulmonary transplantation in cystic fibrosis is currently 8.5 years (and 10 years when considering patients surviving 3 months, ie excluding early mortality). Cystic fibrosis is the pathology associated with better survival after pulmonary transplantation given the young age of patients (28.5 years on average).

The non-respiratory comorbidities associated with transplantation, all underlying pathologies combined, and referenced in the Registry of the International Society for Heart and Lung Transplantation (ISHLT) are: hypertension, diabetes, renal insufficiency, Dyslipidemia, cancers. Their frequency increases with the survival time of transplanted patients. Cystic fibrosis is associated with non-respiratory comorbidities, the frequency of which increases with age - diabetes, osteoporosis, renal insufficiency, hepatopathy, neoplastic pathologies - and may become worse after transplantation.

The main objective is to estimate the incidence of non-respiratory co-morbidities after lung transplantation in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
The population studied is the cohort of patients with cystic fibrosis who received a bipulmonary transplant between 2004 and 2014 in one of the two transplant centers in the Rhône-Alpes region.
  • Pulmonary Failure
  • Cystic Fibrosis
Other: Lung transplantation
To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
Co morbidities after lung transplantation in cystic fibrosis
The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
Intervention: Other: Lung transplantation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
October 30, 2017
June 1, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with clinical diagnosis of cystic fibrosis
  • Patients with Pulmonary transplant between 01/01/2004 and 31/12/2014
  • Patients followed-up in one of the two pulmonary transplantation centers in the Rhône-Alpes region (Lyon, Grenoble)

Exclusion Criteria:

  • Patients followed in Rhône Alpes but transplanted elsewhere in France will not be included.
  • Patient refusing to participate in the study
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT03357913
MUCO TRANSPLAN
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Hospices Civils de Lyon
Hospices Civils de Lyon
Not Provided
Not Provided
Hospices Civils de Lyon
November 2017